Coherus and Junshi Biosciences Report P-III Trial (JUPITER-02) Results of Toripalimab for Recurrent or Metastatic Nasopharyngeal Carcinoma
Shots:
- The P-III trial (JUPITER-02) evaluating toripalimab + gemcitabine & cisplatin vs PBO + CT in 289 patients with recurrent or metastatic NPC
- The results showed a significant & clinical improvement in OS. Additionally, the results are being submitted for presentation at an upcoming medical meeting
- Toripalimab is an anti-PD-1 mAb that blocks PD-L1 binding to the PD-1 receptor. The combination therapy received BTD from the US FDA in 2021 for 1L treatment of recurrent or metastatic NPC and as monotx. for NPC in 2020; FTD from the US FDA for mucosal melanoma & ODD for esophageal cancer, mucosal melanoma, soft tissue sarcoma, and SCLC
Ref: Globe NewsWire | Image: Coherus
Related News:- Coherus Acquires Rights from Klinge Biopharma for Eylea Biosimilar Candidate
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
